Navigation Links
Rash Due to Lung Cancer Drug May Be Linked to Better Survival
Date:12/20/2010

MONDAY, Dec. 20 (HealthDay News) -- Lung cancer patients who develop a rash after treatment with the drug cetuximab (Erbitux) have better outcomes, according to a new study.

German researchers compared hundreds of patients with non-small cell lung cancer who received chemotherapy plus cetuximab and hundreds of patients who received chemotherapy alone. About 70 percent of the patients who received the combination therapy developed an acne-like rash within the first three weeks of treatment.

Compared to other patients, those who developed the rash lived longer (15 months vs. 8.8 months), had better progression-free survival (5.4 months vs. 4.3 months) and had a higher response rate (44.8 percent vs. 32 percent), according to the report by Dr. Ulrich Gatzemeier, from Hospital Grosshansdorf in Germany, and colleagues.

The findings, published online Dec. 19 in The Lancet Oncology, suggest that the early appearance of a skin rash may help identify patients who would be most likely to respond to treatment with cetuximab and gain the greatest survival benefit, the researchers noted.

The study authors concluded that further clinical trials are needed "to verify this finding and assess it fully in the context of possible clinical application."

In a commentary accompanying the report, Dr. Francesco Perrone from the Istituto Nazionale Tumori in Naples, Italy, added: "The only way to verify the hypothesis that skin rash predicts the benefit of cetuximab is a randomized trial that compares interruption versus continuation of cetuximab in patients with skin rash after three weeks of treatment with cetuximab and chemotherapy."

The findings, Perrone continued, "must be validated prospectively before we consider the introduction of cetuximab into clinical practice for the treatment of patients with advanced non-small cell lung cancer."

More information

The American Cancer Society has more about non-small cell lung cancer.

-- Robert Preidt

SOURCE: The Lancet Oncology, news release, Dec. 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rash Due to Lung Cancer Drug May Be Linked to Better Survival
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent ... Gyrociser, an exercise invention which aids in proper muscle development. , "The Gym ... and Creative Director of World Patent Marketing. "Globalization has threatened the future growth ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology: